Literature DB >> 34195803

Direct comparison of high-sensitivity cardiac troponin T and I in the early differentiation of type 1 vs. type 2 myocardial infarction.

Thomas Nestelberger1,2,3, Jasper Boeddinghaus1,2, Maria Rubini Giménez1,2,4, Pedro Lopez-Ayala1,2, Paul David Ratmann1,2, Patrick Badertscher1,2,5, Karin Wildi1,2,6, Desiree Wussler1,2, Luca Koechlin1,2,7, Ketina Arslani1,2, Tobias Zimmermann1,2, Michael Freese1,2, Therese Rinderknecht1,2, Òscar Miró2,8, F Javier Martin-Sanchez2,9, Damian Kawecki2,10, Nicolas Geigy11, Dagmar Keller12, Raphael Twerenbold1,2, Christian Müller1,2.   

Abstract

AIMS: To directly compare the diagnostic accuracy of high-sensitivity cardiac troponin (hs-cTn) T vs. hs-cTnI in the early non-invasive differentiation of Type 1 myocardial infarction (T1MI) due to plaque rupture and atherothrombosis from Type 2 myocardial infarction (T2MI) due to supply-demand mismatch. METHODS AND
RESULTS: In a prospective multicentre diagnostic study, two independent cardiologists centrally adjudicated the final diagnosis of T1MI vs. T2MI according to the fourth universal definition of myocardial infarction (MI), using all available clinical information including cardiac imaging in patients presenting with acute chest pain. Diagnostic accuracy was quantified by the area under the receiver operating characteristics curve (AUC). The most extensively validated hs-cTnT-Elecsys and hs-cTnI-Architect assays were measured at presentation, 1 h, and 2 h. Among 5887 patients, 1106 (19%) had a final diagnosis of MI, including 860 (78%) T1MI and 246 (22%) T2MI. The AUC of hs-cTnT-Elecsys to differentiate T1MI from T2MI was moderate and comparable to that provided by hs-cTnI-Architect: hs-cTnT-Elecsys AUC-presentation 0.67 [95% confidence interval (CI) 0.64-0.71], AUC-1 h 0.70 (95% CI 0.66-0.74), and AUC-2 h 0.71 (95% CI 0.66-0.75) vs. hs-cTnI-Architect AUC-presentation 0.71 (95% CI 0.67-0.74), AUC-1 h 0.72 (95% CI 0.68-0.76), and AUC-2 h 0.74 (95% CI 0.69-0.78), all P = not significant (NS). Similarly, the AUC of absolute changes was moderate and comparable for hs-cTnT-Elecsys and hs-cTnI-Architect (all P = NS). Cut-off concentrations achieving at least 90% specificity for the differentiation of T1MI vs. T2MI were >114 ng/L for hs-cTnT-Elecsys [odds ratio (OR) 4.2, 95% CI 2.7-6.6] and >371 ng/L for hs-cTnI-Architect (OR 4.0, 95% CI 2.6-6.2).
CONCLUSION: hs-cTnT-Elecsys and hs-cTnI-Architect provided comparable, albeit only moderate, diagnostic accuracy for the early differentiation of T1MI vs. T2MI. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov number, NCT00470587, https://clinicaltrials.gov/ct2/show/NCT00470587. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Differentiation; High-sensitivity cardiac troponin; Type 1 myocardial infarction; Type 2 myocardial infarction

Mesh:

Substances:

Year:  2022        PMID: 34195803     DOI: 10.1093/ehjacc/zuab039

Source DB:  PubMed          Journal:  Eur Heart J Acute Cardiovasc Care        ISSN: 2048-8726


  4 in total

1.  Clinical and prognostic implications of high-sensitivity cardiac troponin T concentrations in type 2 non-ST elevation myocardial infarction.

Authors:  K M Eggers; T Baron; A Gard; B Lindahl
Journal:  Int J Cardiol Heart Vasc       Date:  2022-02-12

Review 2.  Type 2 myocardial infarction: a diagnostic and therapeutic challenge in contemporary cardiology.

Authors:  Andrea Carlo Merlo; Roberta Della Bona; Pietro Ameri; Italo Porto
Journal:  Intern Emerg Med       Date:  2022-02-14       Impact factor: 5.472

3.  Myocardial injury in noncardiac surgery.

Authors:  Jungchan Park; Jong-Hwan Lee
Journal:  Korean J Anesthesiol       Date:  2021-10-18

4.  Serial measurements of protein and microRNA biomarkers to specify myocardial infarction subtypes.

Authors:  Christian Schulte; Bhawana Singh; Konstantinos Theofilatos; Nils A Sörensen; Jonas Lehmacher; Tau Hartikainen; Paul M Haller; Dirk Westermann; Tanja Zeller; Stefan Blankenberg; Johannes T Neumann; Manuel Mayr
Journal:  J Mol Cell Cardiol Plus       Date:  2022-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.